BSX
BOSTON SCIENTIFIC CORP
NYSE · Healthcare · Medical - Devices · US
$45.05
+1.49%Year over year
Reported trailing growth
- Revenue
- +13.5%
- EBITDA
- +23.1%
- EBIT
- +51.3%
- EPS
- +46.0%
- Free cash flow
- +9.5%
- Operating cash flow
- +5.7%
Forward estimates
Based on analyst estimates
- Revenue
- +4.3%
- EBITDA
- +35.1%
- EPS
- +34.3%
Three-year CAGR
- Revenue
- +16.5%
- EBITDA
- +23.0%
- EBIT
- +29.6%
- Net income
- +60.5%
- EPS
- +63.5%
- Free cash flow
- +58.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026